

* required for saving **required for completion		
Facility ID:	Event #:	
*Patient ID:	Social Security #:	
Secondary ID:		
Patient Name, Last:	First:	Middle:
*Gender: F M Other	*Date of Birth:	
Ethnicity (Specify):	Race (Specify):	
*Event Type: PNEU	*Date of Event:	
*Post-procedure PNEU: Yes No	Date of Procedure:	
NHSN Procedure Code:	ICD-9-CM Procedure Code:	
*MDRO Infection Surveillance:		
<input type="checkbox"/> Yes, this infection's pathogen & location are in-plan for Infection Surveillance in the MDRO/CDI Module <input type="checkbox"/> No, this infection's pathogen & location are not in-plan for Infection Surveillance in the MDRO/CDI Module		
*Date Admitted to Facility:	*Location:	
Risk Factors		
*Ventilator: Yes No	Location of Device Insertion: _____	Date of Device Insertion: ____/____/____
*For NICU only: Birth weight: _____ grams		
Event Details		
*Specific Event: <input type="checkbox"/> PNU1 <input type="checkbox"/> PNU2 <input type="checkbox"/> PNU3	*Immunocompromised: Yes No	
*Specify Criteria Used: (check all that apply)		
<u>X-Ray</u>		
<input type="checkbox"/> New or progressive and persistent infiltrate	<input type="checkbox"/> Consolidation	<input type="checkbox"/> Cavitation <input type="checkbox"/> Pneumatocoles (in ≤1 y.o.)
Signs & Symptoms		
<input type="checkbox"/> Fever	<input type="checkbox"/> Positive blood culture	
<input type="checkbox"/> Leukopenia or leukocytosis	<input type="checkbox"/> Positive pleural fluid culture	
<input type="checkbox"/> Altered mental status (in ≥70 y.o.)	<input type="checkbox"/> Positive quantitative culture from LRT specimen	
<input type="checkbox"/> New onset/change in sputum	<input type="checkbox"/> ≥5% BAL cells w/bacteria	
<input type="checkbox"/> New onset/worsening cough, dyspnea, tachypnea	<input type="checkbox"/> Histopathologic exam w/ abscess formation, positive quantitative culture of lung parenchyma, or lung parenchyma invasion by fungal hyphae	
<input type="checkbox"/> Rales or bronchial breath sounds [†]	<input type="checkbox"/> Positive culture of virus or <i>Chlamydia</i>	
<input type="checkbox"/> Worsening gas exchange	<input type="checkbox"/> Positive detection of viral antigen or antibody	
<input type="checkbox"/> Hemoptysis	<input type="checkbox"/> 4-fold rise in paired sera for pathogen	
<input type="checkbox"/> Pleuritic chest pain	<input type="checkbox"/> Positive PCR for <i>Chlamydia</i> or <i>Mycoplasma</i>	
<input type="checkbox"/> Temperature instability	<input type="checkbox"/> Positive micro-IF test for <i>Chlamydia</i>	
<input type="checkbox"/> Apnea, tachycardia, nasal flaring with retraction of chest wall or grunting	<input type="checkbox"/> Positive culture or micro-IF of <i>Legionella</i> spp	
<input type="checkbox"/> Hypothermia	<input type="checkbox"/> <i>L pneumophila</i> serogroup 1 antigens in urine	
<input type="checkbox"/> Wheezing, rales, or rhonchi [†]	<input type="checkbox"/> 4-fold rise in <i>L pneumophila</i> antibody titer	
<input type="checkbox"/> Cough	<input type="checkbox"/> Matching positive blood & sputum cultures w/ <i>Candida</i> spp	
<input type="checkbox"/> Bradycardia or tachycardia	<input type="checkbox"/> Fungi or <i>Pneumocystis carinii</i> from LRT specimen	
[†] There are two criteria referring to rales in the PNU 1 signs and symptoms list. Please choose the one that corresponds to the specific algorithm used to identify this pneumonia (Any Patient or Alternate Criteria based on age).		
*Secondary Bloodstream Infection: Yes No		
**Died: Yes No	PNEU Contributed to Death: Yes No	
Discharge Date:	*Pathogens Identified: Yes No *If Yes, specify on pages 2-3.	

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).

Public reporting burden of this collection of information is estimated to average 32 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74, Atlanta, GA 30333, ATTN: PRA (0920-0666).

CDC 57.111 (Front) Rev 3, v6.4

Pathogen #	Gram-positive Organisms									
_____	<i>Staphylococcus</i> coagulase-negative (specify): _____	VANC S I R N								
_____	<i>Enterococcus</i> <i>spp.</i> (specify) _____	AMP S I R N	CIPRO/LEVO/MOXI S I R N	DAPTO S N S N	DOXY/MINO S I R N	GENTHL⁵ S R N	LNZ S I R N			
		STREPHL⁵ S R N	TETRA S I R N	TIG S N S N	VANC S I R N					
_____	<i>Enterococcus</i> <i>faecium</i>	AMP S I R N	CIPRO/LEVO/MOXI S I R N	DAPTO S N S N	DOXY/MINO S I R N	GENTHL⁵ S R N	LNZ S I R N	QUIDAL S I R N		
		STREPHL⁵ S R N	TETRA S I R N	TIG S N S N	VANC S I R N					
_____	<i>Staphylococcus</i> <i>aureus</i>	CHLOR S I R N	CIPRO/LEVO/MOXI S I R N	CLIND S I R N	DAPTO S N S N	DOXY/MINO S I R N	ERYTH S I R N	GENT S I R N		
		LNZ S R N	OX/CEFOX/METH S I R N	QUIDAL S I R N	RIF S I R N	TETRA S I R N	TIG S N S N	TMZ S I R N	VANC S I R N	
Pathogen #	Gram-negative Organisms									
_____	<i>Acinetobacter</i> <i>spp.</i> (specify) _____	AMK S I R N	AMPSUL S I R N	AZT S I R N	CEFEP S I R N	CEFTAZ S I R N	CIPRO/LEVO S I R N	COL/PB S I R N	GENT S I R N	
		IMI S I R N	MERO/DORI S I R N	PIP/PIPTAZ S I R N	TETRA/DOXY/MINO S I R N	TMZ S I R N	TOBRA S I R N			
_____	<i>Escherichia</i> <i>coli</i>	AMK S I R N	AMP S I R N	AMPSUL/AMXCLV S I R N	AZT S I R N	CEFAZ S I R N	CEFEP S I R N	CEFOT/CEFTRX S I R N		
		CEFTAZ S I R N	CEFUR S I R N	CEFOX/CETET S I R N	CHLOR S I R N	CIPRO/LEVO/MOXI S I R N	COL/PB S I R N	ERTA S I R N		
		GENT S I R N	IMI S I R N	MERO/DORI S I R N	PIPTAZ S I R N	TETRA/DOXY/MINO S I R N	TIG S I R N	TMZ S I R N	TOBRA S I R N	
_____	<i>Enterobacter</i> <i>spp.</i> (specify) _____	AMK S I R N	AMP S I R N	AMPSUL/AMXCLV S I R N	AZT S I R N	CEFAZ S I R N	CEFEP S I R N	CEFOT/CEFTRX S I R N		
		CEFTAZ S I R N	CEFUR S I R N	CEFOX/CETET S I R N	CHLOR S I R N	CIPRO/LEVO/MOXI S I R N	COL/PB S I R N	ERTA S I R N		
		GENT S I R N	IMI S I R N	MERO/DORI S I R N	PIPTAZ S I R N	TETRA/DOXY/MINO S I R N	TIG S I R N	TMZ S I R N	TOBRA S I R N	
_____	<i>Klebsiella</i> <i>spp.</i> (specify) _____	AMK S I R N	AMP S I R N	AMPSUL/AMXCLV S I R N	AZT S I R N	CEFAZ S I R N	CEFEP S I R N	CEFOT/CEFTRX S I R N		
		CEFTAZ S I R N	CEFUR S I R N	CEFOX/CETET S I R N	CHLOR S I R N	CIPRO/LEVO/MOXI S I R N	COL/PB S I R N	ERTA S I R N		
		GENT S I R N	IMI S I R N	MERO/DORI S I R N	PIPTAZ S I R N	TETRA/DOXY/MINO S I R N	TIG S I R N	TMZ S I R N	TOBRA S I R N	

Pathogen #	Gram-negative Organisms (continued)									
_____	<i>Serratia marcescens</i>	AMK S I R N	AMP S I R N	AMPSUL/AMXCLV S I R N	AZT S I R N	CEFAZ S I R N	CEFEP S I R N	CEFOT/CEFTRX S I R N		
		CEFTAZ S I R N	CEFUR S I R N	CEFOX/CETET S I R N	CHLOR S I R N	CIPRO/LEVO/MOXI S I R N	COL/PB S I R N	ERTA S I R N		
		GENT S I R N	IMI S I R N	MERO/DORI S I R N	PIPTAZ S I R N	TETRA/DOXY/MINO S I R N	TIG S I R N	TMZ S I R N	TOBRA S I R N	
_____	<i>Pseudomonas aeruginosa</i>	AMK S I R N	AZT S I R N	CEFEP S I R N	CEFTAZ S I R N	CIPRO/LEVO S I R N	COL/PB S I R N	GENT S I R N		
		IMI S I R N	MERO/DORI S I R N	PIP/PIPTAZ S I R N	TOBRA S I R N					
_____	<i>Stenotrophomonas maltophilia</i>	LEVO S I R N	TETRA/MINO S I R N	TICLAV S I R N	TMZ S I R N					
Pathogen #	Fungal Organisms									
_____	<i>Candida spp.</i> (specify) _____	ANID S N S N	CASPO S N S N	FLUCO S S-DD R N	FLUCY S I R N	ITRA S S-DD R N	MICA S N S N	VORI S S-DD R N		
Pathogen #	Other Organisms									
_____	Organism 1 (specify) _____	Drug 1 S I R N	Drug 2 S I R N	Drug 3 S I R N	Drug 4 S I R N	Drug 5 S I R N	Drug 6 S I R N	Drug 7 S I R N	Drug 8 S I R N	Drug 9 S I R N
_____	Organism 2 (specify) _____	Drug 1 S I R N	Drug 2 S I R N	Drug 3 S I R N	Drug 4 S I R N	Drug 5 S I R N	Drug 6 S I R N	Drug 7 S I R N	Drug 8 S I R N	Drug 9 S I R N
_____	Organism 3 (specify) _____	Drug 1 S I R N	Drug 2 S I R N	Drug 3 S I R N	Drug 4 S I R N	Drug 5 S I R N	Drug 6 S I R N	Drug 7 S I R N	Drug 8 S I R N	Drug 9 S I R N

Result Codes

S = Susceptible I = Intermediate R = Resistant NS = Non-susceptible S-DD = Susceptible-dose dependent N = Not tested
[§] **GENTHL and STREPHL results: S=Susceptible/Synergistic and R=Resistant/Not Synergistic**

Drug Codes:

AMK = amikacin	CEFTRX = ceftriaxone	ERYTH = erythromycin	MICA = micafungin	STREPHL = streptomycin – high level test
AMP = ampicillin	CEFUR= cefuroxime	FLUCO = fluconazole	MINO = minocycline	
AMPSUL = ampicillin/sulbactam	CETET= cefotetan	FLUCY = flucytosine	MOXI = moxifloxacin	TETRA = tetracycline
AMXCLV = amoxicillin/clavulanic acid	CHLOR= chloramphenicol	GENT = gentamicin	OX = oxacillin	TICLAV = ticarcillin/clavulanic acid
ANID = anidulafungin	CIPRO = ciprofloxacin	GENTHL = gentamicin – high level test	PB = polymyxin B	TIG = tigecycline
AZT = aztreonam	CLIND = clindamycin	IMI = imipenem	PIP = piperacillin	TMZ = trimethoprim/sulfamethoxazole
CASPO = caspofungin	COL = colistin	ITRA = itraconazole	PIPTAZ = piperacillin/tazobactam	TOBRA = tobramycin
CEFAZ= ceftazidime	DAPTO = daptomycin	LEVO = levofloxacin	QUIDAL = quinupristin/dalfopristin	VANC = vancomycin
CEFEP = cefepime	DORI = doripenem	LNZ = linezolid	RIF = rifampin	VORI = voriconazole
CEFOT = cefotaxime	DOXY = doxycycline	MERO = meropenem		
CEFOX= ceftaxime	ERTA = ertapenem	METH = methicillin		

Pneumonia (PNEU)

Custom Fields

Label

_____	__/__/__
_____	_____
_____	_____
_____	_____
_____	_____
_____	_____
_____	_____
_____	_____

Label

_____	__/__/__
_____	_____
_____	_____
_____	_____
_____	_____
_____	_____
_____	_____
_____	_____

Comments

Large empty text area for comments.